Amantadine for weight gain associated with olanzapine treatment

Walter Deberdt, Andrew Winokur, Patrizia A. Cavazzoni, Quynh N. Trzaskoma, Christopher D. Carlson, Frank P. Bymaster, Karen Wiener, Michel Floris, Alan Breier

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalEuropean Neuropsychopharmacology
Volume15
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

olanzapine
Amantadine
Weight Gain
Brief Psychiatric Rating Scale
Weights and Measures
Diagnostic and Statistical Manual of Mental Disorders
Weight Loss
Depression
Bipolar Disorder
Schizophrenia
Therapeutics
Anxiety
Placebos
Body Weight
Observation

Keywords

  • Amantadine
  • Bipolar I disorder
  • Olanzapine
  • Schizophrenia
  • Weight gain

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Deberdt, W., Winokur, A., Cavazzoni, P. A., Trzaskoma, Q. N., Carlson, C. D., Bymaster, F. P., ... Breier, A. (2005). Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology, 15(1), 13-21. https://doi.org/10.1016/j.euroneuro.2004.03.005

Amantadine for weight gain associated with olanzapine treatment. / Deberdt, Walter; Winokur, Andrew; Cavazzoni, Patrizia A.; Trzaskoma, Quynh N.; Carlson, Christopher D.; Bymaster, Frank P.; Wiener, Karen; Floris, Michel; Breier, Alan.

In: European Neuropsychopharmacology, Vol. 15, No. 1, 01.2005, p. 13-21.

Research output: Contribution to journalArticle

Deberdt, W, Winokur, A, Cavazzoni, PA, Trzaskoma, QN, Carlson, CD, Bymaster, FP, Wiener, K, Floris, M & Breier, A 2005, 'Amantadine for weight gain associated with olanzapine treatment', European Neuropsychopharmacology, vol. 15, no. 1, pp. 13-21. https://doi.org/10.1016/j.euroneuro.2004.03.005
Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP et al. Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology. 2005 Jan;15(1):13-21. https://doi.org/10.1016/j.euroneuro.2004.03.005
Deberdt, Walter ; Winokur, Andrew ; Cavazzoni, Patrizia A. ; Trzaskoma, Quynh N. ; Carlson, Christopher D. ; Bymaster, Frank P. ; Wiener, Karen ; Floris, Michel ; Breier, Alan. / Amantadine for weight gain associated with olanzapine treatment. In: European Neuropsychopharmacology. 2005 ; Vol. 15, No. 1. pp. 13-21.
@article{f73fb8b2d2864e8f9dc4a4783adbc6b8,
title = "Amantadine for weight gain associated with olanzapine treatment",
abstract = "Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5{\%} of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.",
keywords = "Amantadine, Bipolar I disorder, Olanzapine, Schizophrenia, Weight gain",
author = "Walter Deberdt and Andrew Winokur and Cavazzoni, {Patrizia A.} and Trzaskoma, {Quynh N.} and Carlson, {Christopher D.} and Bymaster, {Frank P.} and Karen Wiener and Michel Floris and Alan Breier",
year = "2005",
month = "1",
doi = "10.1016/j.euroneuro.2004.03.005",
language = "English (US)",
volume = "15",
pages = "13--21",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Amantadine for weight gain associated with olanzapine treatment

AU - Deberdt, Walter

AU - Winokur, Andrew

AU - Cavazzoni, Patrizia A.

AU - Trzaskoma, Quynh N.

AU - Carlson, Christopher D.

AU - Bymaster, Frank P.

AU - Wiener, Karen

AU - Floris, Michel

AU - Breier, Alan

PY - 2005/1

Y1 - 2005/1

N2 - Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.

AB - Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.

KW - Amantadine

KW - Bipolar I disorder

KW - Olanzapine

KW - Schizophrenia

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=9644308090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644308090&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2004.03.005

DO - 10.1016/j.euroneuro.2004.03.005

M3 - Article

C2 - 15572269

AN - SCOPUS:9644308090

VL - 15

SP - 13

EP - 21

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -